---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-24-000049"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T07:58:52.370148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

## Summary
- Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).
- Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.
- Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.
- Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.
- Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver.

## SEC filing metadata
- accession: 0001082554-24-000049
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/0001082554-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/uthr-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-24-000049
- JSON: https://secwatch.observer/filing/0001082554-24-000049.json
- Plain text: https://secwatch.observer/filing/0001082554-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.